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Fetal chromosomal aneuploidies can lead to fetal loss and 
major birth defects. The best known chromosomal aneu-
ploidy is Down syndrome, or medically termed trisomy 21, 
where the affected individual has an extra full or partial 
copy of chromosome 21. The extra copy of genetic material 
is the culprit for causing developmental problem for affect-
ed individuals. Three types of Down syndrome exist: tri-
somy 21 accounts for 95% of cases, translocation accounts 
for about 4% and mosaicism accounts for about 1%. Less 
common chromosomal aneuploidies include Edward syn-
drome (trisomy 18), Patau syndrome (trisomy 13), Turner 
syndrome (45, X), Klinefelter syndrome (47, XXY), and 47, 
XYY. Many trisomic fetuses die in utero, and could account 
for up to 13% of all stillbirths and neonatal death. Even if 
the fetus would survive, the extra copy of chromosome 21 
will affect the baby’s physical and intellectual development 
into adulthood, causing significant personal, social and 
economic burden.   
The incidence of combined chromosomal abnormalities 
is as high as one in 160 in the United States or one in 60 in 
China. Such incidence increases as the mother ages and it 
could reach as high as 2.5% with maternal age over 35 in 
China. The estimated incidence of Down syndrome is be-
tween 650 and 1000 live births. Such incidence increases 
significantly as maternal age increases, affecting one in 350 
for mothers aged 35, one in 106 at age of 40 and as high as 
one in 30 at 45 years of age. It is therefore important for 
fetus with chromosomal abnormalities to be detected, as 
early as possible. Prenatal testing for chromosomal abnor-
malities is in common practice. Both screening and diag-
nostic methods have been deployed. Screening methods 
involve serum marker analysis and/or ultrasound examina-
tions for parameters such as nuchal translucency. Such 
methods usually suffer from low sensitivity and specificity. 
Diagnostic tests usually follow if screening show positive 
results.   
Diagnostic tests traditionally are invasive in nature. Am-
niocentesis and chorionic villus sampling are two conven-
tional invasive methods for prenatal diagnosis of fetal 
chromosomal aneuploidies. These two methods are highly 
accurate; however, they both require invasive sampling of 
fetal materials and carry the risk of fetal loss. The landmark 
discovery of cell-free fetal nucleic acids in maternal plasma 
by Dennis Lo in 1997 opened the door to develop noninva-
sive prenatal diagnosis methods to detect fetal chromosomal 
aneuploidies [1]. The robust detection of fetal chromosomal 
aneuploidies using maternal plasma DNA is challenging, 
due to the relatively low fractional concentration of circu-
lating fetal DNA. In 2008, the reliable detection of fetal 
trisomy 21 using massively parallel sequencing of maternal 
plasma DNA reported by Lo’s and Gao’s labs [2] set the 
foundation of noninvasive prenatal testing. Subsequently, 
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large scale validation of these observations has been con-
ducted by several groups around the world.   
Previously, most studies utilize the sequencing-by-  
synthesis platform for sequencing maternal plasma DNA for 
aneuploidy detection. Yuan et al. [3], in a proof-of-concept 
study, demonstrated that semiconductor sequencing could 
also be used for noninvasive prenatal detection of fetal 
chromosomal aneuploidy, with the advantage of a shorter 
turnaround time. At the time of the study, the authors 
demonstrated that all 13 chromosomal aneuploidies were 
correctly identified with a 24-h processing time. Because of 
the number of samples they processed is very small, only 13 
cases, six with trisomy 21, two with trisomy 18 and one 
with trisomy 13, and it is not a prospective study, the au-
thors cautioned, however, “a further large-scale study is 
needed to determine the imprecision of noninvasive fetal 
aneuploidy detection with this system”. Such a large-scale 
study was achieved recently.  
In a paper published in the Proceedings of the National 
Academy of Sciences of the United States of America last 
month, led by the groups of Drs. Liao Can, Liu HaiLiang, 
Zhang XiaoZhuang and Zhang Kang [4], based on both ret-
rospective (515 subjects) and prospective (1760 subjects) 
study of a total of 2275 pregnant subjects, it clearly demon-
strated that a benchtop semiconductor sequencing platform 
(SSP) is suitable and effective for non-invasive diagnostic 
of fetal chromosomal abnormalities with a fast turnaround 
time at a clinical setting. The strength of this paper over the 
previous paper is two-fold: first, a very large sample size; 
second, it contains both retrospective and prospective study 
design. In the retrospective study, 515 subjects who had full 
karyotyping results were used in the analysis. All 55 fetal 
trisomy 21 cases were identified using the SSP with a sensi-
tivity and specificity of 99.94% and 99.46%. The SSP also 
detected 16 trisomy 18 cases with 100% sensitivity and 
99.24% specificity and three trisomy 13 cases with 100% 
sensitivity and 100% specificity. Furthermore, 15 fetuses 
with sex chromosome aneuploidies (10 45, X, 2 47, XYY, 2 
47, XXX, and 1 47, XXY) were detected. In the prospective 
study, 1760 subjects without karyotyping results were ana-
lyzed. The SSP analysis detected nine fetuses with trisomy 
21, three with trisomy 18, three with trisomy 13, and one 
with 45, X. To confirm the detection, the authors randomly 
selected six positive T21 samples, and the 45, X sample to 
perform full karyotyping and confirmed all of them to be 
true positive.    
In conclusion, this is the first large-scale clinical study to 
systematically identify chromosomal aneuploidies based on 
cell-free fetal DNA using SSP. It also provides a reliable  
and cost effective method for large-scale noninvasive 
screening for chromosomal aneuploidies in a clinical setting. 
There are two understandable shortcomings of this paper. 
First, for the prospective arm of the study, there are insuffi-
cient cases with validated outcome. Second, because the 
total number of detected positive samples is small (nine 
fetuses with trisomy 21, three with trisomy 18, three with 
trisomy 13, and one with 45, X), instead of randomly se-
lecting samples, all cases should have a complete karyotyp-
ing and report the results. 
It is expected that the cost of DNA sequencing will be 
further reduced in the near future owing to the advancement 
of sequencing technology, computing power as well as de-
velopment of new bioinformatics tools. The use of targeted 
sequencing by a number of commercial vendors would po-
tentially provide a cheaper service, breaking the long sought 
200 USD or 1000 RMB in China barrier for routine use. 
Noninvasive prenatal measurement of fetal genome using 
cell free DNA in pregnant women blood suggested that the 
prenatal testing based on cell free-DNA sequencing can be 
used to detect not only fetal chromosomal aneuploidies, but 
also many inherited and de novo genetic diseases [5]. Re-
cent regulation on prenatal testing set forth by the Chinese 
government should be welcomed by the general public. It is 
understood that standardization of clinical trial, testing pro-
cedures, pre-testing counseling, as well as post-testing fol-
low-up would ultimately benefit the well-being of the fetus 
and pregnant mother.  
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